Dexcom (NASDAQ: DXCM) director awarded 7,061 restricted stock units

Rhea-AI Filing Summary

Osterloh Albert Frederick IV reported acquisition or exercise transactions in this Form 4 filing.

DexCom, Inc. director Albert Frederick Osterloh IV reported receiving a grant of 7,061 restricted stock units of common stock. The award was made at a stated price of $0.00 per share and represents a contingent right to receive 7,061 DexCom common shares.

The restricted stock units vest in three equal annual installments from the grant date, meaning one‑third of the units is scheduled to vest each year over three years, subject to the grant’s terms.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Osterloh Albert Frederick IV

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		A		7,061(1)	A	$0	7,061	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Albert Frederick Osterloh IV	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did DexCom (DXCM) report for Albert Frederick Osterloh IV?

DexCom reported that director Albert Frederick Osterloh IV received a grant of 7,061 restricted stock units of common stock. These units were awarded at a stated price of $0.00 per share and give a contingent right to receive DexCom common shares.

How many DexCom (DXCM) restricted stock units were granted in this Form 4?

The Form 4 shows a grant of 7,061 restricted stock units of DexCom common stock. Each unit represents a contingent right to receive one share of common stock, subject to the vesting schedule described in the filing’s footnote.

What is the vesting schedule for the 7,061 DexCom (DXCM) restricted stock units?

The 7,061 restricted stock units vest in three equal annual installments from the grant date. One‑third of the units is scheduled to vest each year over three years, assuming the conditions of the grant continue to be satisfied.

Does the DexCom (DXCM) director pay for the 7,061 restricted stock units?

The filing reports a transaction price of $0.00 per share for the 7,061 restricted stock units. This indicates the director did not pay cash consideration per share for the award, which is typical for equity compensation grants to directors or executives.

What does each DexCom (DXCM) restricted stock unit in this grant represent?

Each restricted stock unit in this grant represents a contingent right to receive one share of DexCom common stock. Actual shares are delivered only upon vesting of the units according to the three‑year annual installment schedule disclosed in the Form 4 footnote.

Is the 7,061-unit DexCom (DXCM) award a direct or indirect holding?

The Form 4 classifies the 7,061 restricted stock units as a direct holding, indicated by the ownership code and direct-or-indirect flag. After this grant, the total reported common stock-equivalent holdings following the transaction are 7,061 units.